NovaBay Pharmaceuticals, Inc. (NBY)
NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.1300+0.0100 (+0.89%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 1.1200 |
| Open | 1.1000 |
| Bid | 1.1100 x 2900 |
| Ask | 1.1100 x 4000 |
| Day's Range | 1.0400 - 1.4000 |
| 52 Week Range | 0.2400 - 1.9400 |
| Volume | 24,395,652 |
| Avg. Volume | 5,192,325 |
| Market Cap | 47.214M |
| Beta (5Y Monthly) | 3.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4070 |
| Earnings Date | Mar 24, 2021 - Mar 29, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.63 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Business Wire
NovaBay CEO Issues Letter to Stockholders
NovaBay announces Avenova and CelleRx Clinical Reset to be available in brick-and-mortar stores.
- Business Wire
NovaBay Pharmaceuticals Now Included in EPA N Listing of Products That Kill SARS-CoV-2
NovaBay Pharmaceuticals announces its proprietary hypochlorous acid solution has received EPA approval for SARS-CoV-2 kill claim.
- Business Wire
NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement
© 2021 Verizon Media. All rights reserved.
